FDA approves ‘Rukobia’ for HIV patients with limited treatment options
Category: #health  | By Mateen Dalal  | Date: 2020-07-04 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

FDA approves ‘Rukobia’ for HIV patients with limited treatment options

The use of antiretroviral therapies (ART) to battle HIV (Human Immunodeficiency Virus) is one of the great achievements of modern medicine. The ART medications can transform HIV from a fatal infection into a more manageable, chronic disease. As per the United Nations, the increased use of ART has been the main reason for a 48% decrease in AIDS-related deaths.

Recently, the ART landscape in the U.S got a new impetus when the US FDA (Food and Drug Administration) approved a new antiretroviral drug named Rukobia (fostemsavir) for the treatment of patients with AIDS. The agency has approved this drug to treat patients who have tried several HIV medications and whose infection can’t be treated with other treatments because of intolerance, resistance, and safety conditions.

Speaking on which, Jeff Murray, M.D, Deputy Director of FDA’s Division of Antivirals said that this authorization marked a new class of antiretroviral therapy that might benefit patients who tried several treatment options.

Mr. Murray added that the new antiretroviral drug is pivotal for patients who resist multiple HIV treatment options- helping people to potentially live longer and healthier lives.

Sources cite that the efficacy and safety of Rukobia were assessed in a clinical trial of 371 treatment-experienced patients who continued to have greater levels of (HIV-RNA) in their blood despite being on antiretroviral drugs.

After 24 weeks of evaluations, data demonstrated that around 53% of participants have attained HIV RNA suppression, where HIV levels were low enough to be considered undetectable. After, 96 weeks, 60% of participants demonstrated HIV RNA suppression.

Nausea was the most common adverse event witnessed in a clinical trial. Serious adverse events included elevations in liver enzymes among patients also diagnosed with hepatitis C or B virus, and immune reconstitution syndrome.

The US FDA granted approval of this drug to ViiV Healthcare under fast track, priority review, and breakthrough therapy designations.

Source Credit - https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options#:~:text=Today%2C%20the%20U.S.%20Food%20and,resistance%2C%20intolerance%20or%20safety%20considerations.

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Apollo plans to expand looking at average occupancy surge

Apollo plans to expand looking at average occupancy surge

By Mateen Dalal

Apollo Hospitals Enterprises Ltd., one of India's leading healthcare providers, is reportedly targeting to increase the average occupancy rate in its hospitals to 68-70% for the fiscal year 2024. The company recently announced impressive finan...

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...